[1] |
Dagotto G, Yu J, Barouch DH. Approaches and challenges in SARS-CoV-2 vaccine development[J]. Cell Host Microbe,2020,28(3):364-370.
|
[2] |
王凌航. 新型冠状病毒感染的特征及应对[J/CD]. 中华实验和临床感染病杂志(电子版),2020,14(1):1-5.
|
[3] |
Krammer F. SARS-CoV-2 vaccines in development[J]. Nature,2020,586(7830):516-527.
|
[4] |
Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding[J]. Lancet,2020,395(10224):565-574.
|
[5] |
Da Silva PG, Mesquita JR, De Sao Jose Nascimento M, et al. Viral, host and environmental factors that favor anthropozoonotic spillover of coronaviruses: An opinionated review, focusing on SARS-CoV, MERS-CoV and SARS-CoV-2[J]. Sci Total Environ,2021,750:141483.
|
[6] |
Yao H, Song Y, Chen Y, et al. Molecular architecture of the SARS-CoV-2 virus[J]. Cell,2020,183(3):730-738. e13.
|
[7] |
Wrapp D, Wang N, Corbett KS, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation[J]. Science, 2020,367(6483):1260-1263.
|
[8] |
Andrew R, Nick L, Oliver P, et al. Prelimiary genomic characterisation of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutation[EB/OL].
URL
|
[9] |
中华人民共和国国家卫生健康委. 新型冠状病毒感染的肺炎防控中常见医用防护用品使用范围指引(试行)[J]. 中国护理管理,2020,20(2):1672-1756.
|
[10] |
中华人民共和国国家卫生健康委. 新型冠状病毒肺炎防控方案(第七版)[J]. 中国感染控制杂志,2020,19(11):1042-1048.
|
[11] |
中华人民共和国国家卫生健康委. 新型冠状病毒肺炎诊疗方案(试行第八版)[J]. 中华临床感染病杂志,2020,13(5):321-328.
|
[12] |
李六亿,巩玉秀,张流波. 经空气传播疾病医院感染预防与控制规范WS/T 511-016[J]. 中国感染控制杂志,2017,16(5):490-492.
|
[13] |
中华人民共和国卫生部. 医院隔离技术规范[J]. 中华医院感染学杂志,2009,19(13):1612-1616.
|
[14] |
中华人民共和国国家卫生健康委. 关于印发不同人群预防新型冠状病毒感染口罩选择与使用技术指引的通知[J]. 中华人民共和国国家卫生健康委员会公报,2020,(1):30-32.
|
[15] |
中华人民共和国国家卫生健康委员会. 新型冠状病毒实验室生物安全指南(第二版)[EB/OL].
URL
|
[16] |
中华医学会病理学分会,中国医师协会病理科医师分会. 关于新型冠状病毒肺炎疫情防控期间病理科工作的指导意见(试行)[J]. 中华病理学杂志,2020,66(4):294-296.
|
[17] |
Gao Q, Bao L, Mao H, et al. Development of an inactivated vaccine candidate for SARS-CoV-2[J]. Science,2020,369(6499):77-81.
|
[18] |
高乐涛. 我国传统与新型疫苗应用现状概述[J]. 中国保健营养,2017,27(20):62.
|
[19] |
成传刚,慕婷,袁军, 等. 重组病毒载体疫苗研究进展[J]. 中国病毒病杂志,2018,8(4):318-328.
|
[20] |
Smith TRF, Patel A, Ramos S, et al. Immunogenicity of a DNA vaccine candidate for COVID-19[J]. Nat Commun,2020,11(1):2601.
|
[21] |
Wang F, Kream RM, Stefano GB. An evidence based perspective on mRNA-SARS-CoV-2 vaccine development[J]. Med Sci Monit,2020,26:e924700.
|
[22] |
武汉生物制品研究所有限责任公司. 新型冠状病毒灭活疫苗(Vero细胞)随机,双盲,安慰剂平行对照Ⅰ/Ⅱ期临床试验[EB/OL]. [2020-05-29].
URL
|
[23] |
中国生物. 重磅!中国生物新冠灭活疫苗Ⅰ/Ⅱ期临床研究揭盲[EB/OL]. [2020-06-21].
URL
|
[24] |
中国生物. 全球首个新冠灭活疫苗国际临床(Ⅲ期)试验正式启动[EB/OL]. [2020-6-24].
URL
|
[25] |
Wang H, Zhang Y, Huang B, et al. Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2[J]. Cell,2020,182(3):713-721. e9.
|
[26] |
北京生物制品研究所有限责任公司. 新型冠状病毒(2019-CoV)灭活疫苗(Vero细胞)Ⅰ/Ⅱ期临床试验[EB/OL]. [2020-05-29].
URL
|
[27] |
Chinese Academy of Medical Sciences. Safety and immunogenicity study of an inactivated SARS-CoV-2 vaccine for preventing against COVID-19[EB/OL]. [2020-06-08].
URL
|
[28] |
孟彤彤,孔庆福,王富珍, 等. 新型冠状病毒灭活疫苗研究进展[J]. 中国疫苗和免疫,2020,26(5):590-596.
|
[29] |
Widge AT, Rouphael NG, Jackson LA, et al. Durability of responses after SARS-CoV-2 mRNA-1273 vaccination[J]. N Engl J Med,2020. [Online ahead of print].
|
[30] |
Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine[J]. N Engl J Med,2020. [Online ahead of print].
|
[31] |
Voysey M, Clemens SaC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK[J]. Lancet,2020. [Online ahead of print].
|
[32] |
Logunov DY, Dolzhikova IV, Zubkova OV, et al. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia[J]. Lancet,2020,396(10255):887-897.
|